This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, randomised clinical trial that was carried out at 54 centres throughout UK. The patients were randomised using a central telephone randomisation system based on minimisation. The groups were stratified according to duration of illness, frequency of primary care visits, age and gender. The length of follow-up was 1 year. At the end of the follow-up period, data for 56 patients (13%) were missing. In particular, 16 patients were lost to follow-up in the guidebook group, 17 in the guidebook plus self-help group, and 23 in the control group. These data were imputed using logistic regression. However, GP records were reviewed for 139 of 141 patients in the guidebook group, 131 of 140 in the guidebook plus self-help group, and 134 of 140 in the control group. Blinding was not performed.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The primary outcome measure was the number of primary care consultations recorded from the primary care records, and the patients' clinical global impression scores. The global impression scale requires patients to rate two items, the severity of their IBS symptoms and the improvement in symptoms. These were both rated on a 7-point scale (from unbearable to no symptoms for 'severity', and from very much worse to very much improved for 'improvement'). The secondary outcome measures were hospital consultation rates, symptom severity, quality of life scores, and health status (using the GHQ-28 and the SF-36). The patients rated their symptoms using four visual analogue scales representing severity of abdominal pain, abdominal distension, constipation and diarrhoea. Additional questions allowed the authors to identify whether the Rome II criteria for IBS had been fulfilled. Patients completed the IBS-QOL, a disease-specific instrument for measuring quality of life. As for health status, the GHQ-28 is a 28-item measure of general psychological well-being, while the SF-36 has eight sub-scales rating physical function, physical role limitation, mental health, emotional role limitation, social function, energy and vitality, bodily pain and health perceptions.
The baseline comparability of the study groups was not explicitly discussed, but the methods used for randomisation should have ensured comparability among patient groups. A multiple regression analysis was performed using primary and secondary outcomes and patient characteristics as the covariates. Patient characteristics included gender, age, marital status, education, time with condition, family history of IBS, use of information sources, Eysenck neuroticism, extroversion, and psychoticism scores.
Effectiveness results
Over the 1-year time period, there was a reduction of 1.56 primary care visits per patient (95% confidence interval, CI: 1.15 to 1.98; p<0.001) in the guidebook group in comparison with conventional care. This represented a 60% reduction in visits. The guidebook plus self-help group did not add any benefit. Improvements in the global impression scores were comparable between groups.
Hospital visits were significantly lower for patients in the guidebook group compared with those in the control group. The mean difference was 0.22 visits (95% CI: 0.01 to 0.42) after controlling for baseline levels (40% reduction). The hospital visits in the guidebook plus self-help group were similar to those of the guidebook alone group.
Symptoms and quality of life scores were comparable among the three groups. In terms of self-care activities, there was evidence that the use of dietary treatments (0.19, 95% CI: 0.01 to 0.37; p=0.035) and relaxation therapy (0.23, 95% CI: 0.06 to 0.41; p=0.011) was higher for the guidebook groups, but no differences were observed with the use of exercise, alternative products, or complementary therapies.
Differences in the GHQ scores did not reach statistical significance.
Most dimensions of the SF-36 were comparable between groups, except for scores for health perceptions and scores on the physical role limitation scale. Scores for health perceptions were significantly higher for patients who received the guidebook (5.11, 95% CI: 0.55 to 9.68; p=0.029), while scores on the physical role limitation scale were significantly improved for those assigned to the self-help group (6.80, 95% CI: 0.85, to 12.75; p=0.026).
Clinical conclusions
The effectiveness analysis showed that, compared with conventional care, the guidebook intervention significantly reduced consultation visits and hospital visits for patients with IBS. The guidebook plus self-help intervention did not confer any additional benefit. The interventions had no significant impact on quality of life and symptoms.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
The analysis of the costs was carried out from the perspective of the NHS. It included the costs of GP visits, hospital visits and prescribed drugs. Unit costs were presented for most items, but little information on resource consumption was provided. Resource use was estimated from the actual consumption of resources incurred by the sample of patients in the clinical trial. The costs of GP visits were estimated from the national average cost of a surgery consultation. The cost of a hospital visit reflected the national average cost of a gastroenterology outpatient follow-up attendance with no investigation or procedure. The drug costs were estimated using the British National Formulary. Average dosages were used. Discounting was not relevant as the costs were incurred during 1 year. The price year was not reported, but the unit costs were taken from sources published in 2002 and 2003.
